Today a new vaccine against malaria, largely developed in Nijmegen, is being tested for the first time in volunteers at Radboudumc.
Almost half a million people die of malaria every year, especially young children in Africa. The germs of malaria (the parasites) are transferred from one person to another via the malaria mosquito. This new vaccine aims to prevent this transmission, so malaria cannot spread further.
Scientists from Nijmegen were at the forefront of this vaccine in the 1990s, when they discovered a protein of the parasite (the Pfs48 / 45 protein) that plays an essential role in the transmission of the malaria parasite to the mosquito. By switching off this protein, the formation of new parasites in the mosquito can be blocked. This prevents other people from being infected via a mosquito bite. The vaccine doesn’t prevent you from getting malaria yourself, but it prevents the spread of malaria in other people. This was a completely new concept at the time. Together with Danish colleagues from the Statens Serum Institute, this protein has now been developed into a form (called R0.6C) that can be administered as a vaccine against malaria.
The so-called R0.6C vaccine is a recombinant product that targets the Pfs48 / 45 protein. This vaccine must generate antibodies (antibodies) against this protein in humans. If someone with malaria and the administered vaccine is bitten by a mosquito, that mosquito will also ingest the antibodies. Those antibodies will block the development of the parasites in the mosquito. This prevents further spread of malaria in the human population.
Whether the concept works must be carefully tested of course. The first test (phase 1 study), which is now being carried out on volunteers at Radboudumc, is investigating the safety of this vaccine. It’s also being examined whether antibodies that can prevent the transmission of malaria are indeed formed in the blood of the volunteers.
More at www.radboudumc.nl/malariavaccin
More at malaria
Related news items
Biomarkers for pyridoxine-dependent epilepsy identified by untargeted metabolomics and infrared ion spectroscopy24 June 2021
Karlien Coene, theme Metabolic Diseases, and colleagues published in the Journal of Clinical Investigation that untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy.read more
The international dataset for colorectal local excisions is published16 June 2021
Iris Nagtegaal and colleagues presented their first paper on the colorectal cancer dataset and published this in the journal Gastroenterology.read more